Applied Therapeutics Reports Q2 Loss

Applied Therapeutics (APLT) reported a Q2 2025 GAAP EPS loss of $(0.15), which beat estimates, but posted no recurring revenue and continued operating losses. The company's cash and equivalents sharply declined from $79.4 million to $30.4 million, underscoring significant financial sustainability concerns. While its lead candidate, govorestat, showed positive clinical data with an upcoming FDA meeting, the rapid cash burn necessitates securing additional capital or partnerships to fund ongoing clinical development and operations.

Analysis

Applied Therapeutics (APLT) reported a mixed Q2 2025, with a GAAP EPS loss of $(0.15) narrowly beating analyst estimates of a $(0.17) loss but worsening from a $(0.13) loss in the prior year. The headline beat is overshadowed by severe fundamental weaknesses, most critically a precarious cash position. The company's cash and equivalents plummeted from $79.4 million to $30.4 million in the first six months of 2025, indicating a burn rate that provides a runway of likely less than two quarters and raises significant concerns about financial sustainability. Operationally, the company recognized no revenue while net losses reached $21.3 million, exacerbated by a 24.5% year-over-year increase in G&A expenses to $13.2 million. On the clinical front, the outlook is bifurcated: the lead candidate, govorestat, demonstrated positive Phase 2/3 trial data for CMT-SORD, with a pivotal FDA meeting for its NDA submission scheduled for next quarter. However, this progress is contrasted by the classic galactosemia program remaining in limbo following an FDA Complete Response Letter. While a recent out-licensing deal for AT-001 provides some near-term cash, it is insufficient to alter the urgent need for substantial new funding to support operations and advance its core pipeline.

Key Decisions for Investors

• Investors must recognize the critical risk posed by the rapid cash burn, as the remaining $30.4 million implies a highly probable and potentially dilutive capital raise is required in the immediate future.
• The upcoming FDA meeting for govorestat is a key binary catalyst; a positive outcome could significantly de-risk the company's lead asset, while any delay or negative feedback would severely impact its valuation.
• Given the promising lead candidate is weighed against a recent regulatory setback and a precarious financial state, positions in APLT are speculative and should be sized according to a high tolerance for risk.